Skip to content

A randomized controlled study of hybrid ablation based on left pulmonary vein isolation through left thoracic approach in the treatment of long-term persistent atrial fibrillation

A randomized controlled study of hybrid ablation based on left pulmonary vein isolation through left thoracic approach in the treatment of long-term persistent atrial fibrillation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200056679
Enrollment
Unknown
Registered
2022-02-10
Start date
2022-02-14
Completion date
Unknown
Last updated
2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation

Interventions

1:left atrium ablation
2:both left and right atrium ablation

Sponsors

Chao-Yang Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients with long-term persistent atrial fibrillation have palpitations or cardiac insufficiency (NYHAII-III) symptoms and have the desire to restore sinus rhythm; 2. Agree to the operation method and sign the operation consent.

Exclusion criteria

Exclusion criteria: 1. Poor cardiac function (NYHA IV) or general condition of the body, unable to tolerate surgery; 2. There are bleeding events in the last month (such as gastrointestinal bleeding, intracranial hemorrhage, etc.); 3. Severe coronary artery disease (myocardial infarction, coronary angiography with bypass indication in the last month), or moderate to severe valvular disease.

Design outcomes

Primary

MeasureTime frame
atrial fibrillation;atrial flutter;atrial tachycardia;

Secondary

MeasureTime frame
Pericardial tamponade;Acute heart failure;Operation time;

Countries

China

Contacts

Public ContactXingpeng Liu

Chao-Yang Hospital, Capital Medical University

xpliu71@vip.sina.com+86 13910835371

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026